Medicare has launched a new trial program, the GLP-1 Bridge, offering select brand-name weight loss drugs for a mere $50 monthly copay. This temporary initiative, which began Wednesday and runs until the end of next year, marks the first time most older adults can access these medications for weight loss through insurance. While presented as a relief, the program effectively shifts the true cost of these expensive drugs, often hundreds of dollars per month, onto the American taxpayer through Medicare subsidies.
Elite Interests and Public Burden
The GLP-1 Bridge program directly benefits pharmaceutical giants like Eli Lilly, maker of Foundayo tablets and Zepbound KwikPens, and Novo Nordisk, which produces Wegovy injections and tablets. These companies see their FDA-approved weight loss drugs now subsidized by a federal program, ensuring a steady revenue stream. Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services (CMS), stated his hope that the program will "collect data to potentially work toward longer-term coverage," alongside his claim of providing "immediate relief to cash-strapped older Americans." This dual justification highlights the administrative state's interest in expanding its reach under the guise of temporary assistance.
Of the more than 70 million Americans enrolled in Medicare, KFF's Juliette Cubanski noted that at least 10 million are overweight or obese. However, she clarified that only a "narrower slice" of this group will actually gain access to the program, despite the broad financial implications for all taxpayers. Oz refused to speculate on the number of beneficiaries, preferring to wait for program data.
Circumventing Accountability
To qualify for this subsidized treatment, individuals must possess a body mass index (BMI) of 35 or higher, or a BMI of 27 or higher coupled with another health condition, such as a prior heart attack or stroke or prediabetes. The program explicitly excludes those already receiving GLP-1 coverage for conditions like diabetes or sleep apnea. Payments made under the Bridge program do not count toward deductibles or out-of-pocket maximums, further obscuring the true financial burden on the system.
The federal government's ability to maintain this access is limited, as Congress has not authorized permanent Medicare coverage for weight loss drugs. The Bridge program is scheduled to sunset on December 31, next year. CMS had previously indefinitely delayed another voluntary pilot program, BALANCE, earlier this year due to "many Part D insurers" being "reluctant to sign up." This reluctance from private insurers highlights the financial risks and administrative complexities that the federal agency is now navigating through a temporary, taxpayer-funded workaround. Oz himself admitted that a permanent federal law is "not essential right now," preferring to wait for data before Congress debates the long-term solution.
The Real Cost to the People
While some individuals, like 78-year-old California resident Gloria Dralla, express relief, having lost 40 pounds after buying lower-cost Wegovy in Europe, their personal benefit comes at a collective cost. Dralla stated, "This drug should be made available at a reasonable price for everybody who’s got weight loss problems," a sentiment that overlooks the mechanism of taxpayer subsidy. Meanwhile, others, like 71-year-old Katie Smith from Virginia, with a BMI of 33, face frustration. She is unsure of her eligibility and was quoted $700 a month for the medication, a price she cannot afford. Her inability to access the program underscores the arbitrary nature of who benefits from these elite-driven initiatives, leaving many native working-class Americans to bear the costs without receiving the promised relief. The administrative state continues to expand its reach, funneling public funds into corporate coffers, while the long-term health and financial stability of the nation remain unaddressed.